Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
Hajime NagasuYuichiro YanoHiroshi KanegaeHiddo J Lambers HeerspinkMasaomi NangakuYosuke HirakawaYuka SugawaraNaoki NakagawaYuji TaniJun WadaHitoshi SugiyamaKazuhiko TsuruyaToshiaki NakanoShoichi MaruyamaTakashi WadaKunihiro YamagataIchiei NaritaKouichi TamuraMotoko YanagitaYoshio TeradaTakashi ShigematsuTadashi SofueTakafumi ItoHirokazu OkadaNaoki NakashimaHiromi KataokaKazuhiko OheMihoko OkadaSeiji ItanoAkira NishiyamaEiichiro KandaKohjiro UekiNaoki KashiharaPublished in: Diabetes care (2021)
The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.